CMS's current inclusion of noncovered self-administered drug prices in Medicare Part B payment calculations inflates costs for Stelara biosimilars. OIG recommends revising pricing methodology to achieve savings.

Study shows biosimilar bevacizumab reduces Medicare costs for metastatic colorectal and lung cancer treatments, expanding patient access without raising spending.